NorthWest Biotherapeutics Inc (NWBO)

[beartrap12]

Larppis, I haven’t yet found the wording but I think the latest 10Q points out that L and Direct are part of NWBO’s platform technology based on the same treatment, just delivered differently.

We have developed a platform technology, DCVax®, which uses activated dendritic cells to mobilize a patient’s own immune system to attack their cancer.
Both L and Direct have this in common, so basically the same
Our lead product, DCVax®-L, is designed to treat solid tumor cancers in which the tumor can be surgically removed….. Our second product, DCVax®-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and included treatment of a diverse range of more than a dozen types of cancers.

I added what’s in red. Below is the definition of “Platform” on Pharmaguideline.com.

Platform technology basically provides a common method, common procedure, common procedure which may be worked upon to have further enhancements in research, development, and manufacturing. In this case, we are producing a standard protocol whereby we can build further strategies that can lead to further development of the product.
Read more at: https://www.pharmaguideline.com/2021/09/platform-technology.html

Direct’s way of building on the DCVax platform was to find a way to deliver the activated cells without requiring lysate from the tumor, otherwise, avoiding the need to surgically remove the tumor, which can’t be done on inoperable tumors. (Begs the question will we need L in the future?? There may be some benefit to having the lysate. I don’t know)

To be honest, Larppis, FDA may or may not agree with management that the two treatments are the same. Regardless, We may still need a second Direct clinical trial to further improve or prove the effectiveness of injecting DCVax treatment directly into the tumor.
We will see, probably sooner than many expect. Also, the trials may be very short. Dr. Bosch has found a connection between patients that survived to 8 weeks, with certain telltale changes in their tumor, and much longer than expected survival in patients overall.
Listen to his podcasts carefully. Eight weeks after all patients begin treatment we know who will benefit.
Then take quite a few minutes to read the patent. Mind blowing!